Wells Fargo Gives Rapport Therapeutics an “Overweight” Rating
Wells Fargo analyst rates Rapport Therapeutics as Overweight with $43 target, citing strong Phase 2a seizure data and promising efficacy.
NOTRELOAD AI
Morgan Stanley Cuts Humana Rating Amid Medicare Advantage Concerns
Morgan Stanley downgraded Humana to Underweight, citing policy risks and disappointing Medicare Advantage updates, with a new price target of $174.
Hain Celestial Sells Snacks Business for $115M to Focus on Core Brands
Hain Celestial sells North American snacks unit including Terra chips to Canadian manufacturer for $115M, streamlining portfolio to boost margins and reduce debt.
MoonLake's Sonelokimab Gets FDA Fast Track for Rare Skin Disease
MoonLake Immunotherapeutics receives FDA Fast Track designation for sonelokimab in palmoplantar pustulosis, accelerating development for this untreated skin condition.
Trump Launches $12B Strategic Minerals Stockpile to Counter China
President Trump unveils Project Vault, a $12 billion initiative to stockpile critical minerals, reducing US dependence on China and protecting manufacturers from supply disruptions.
Aquestive Therapeutics Gets FDA Feedback on Anaphylm – Quick Resolution Expected
Aquestive Therapeutics receives FDA Complete Response Letter for Anaphylm with packaging-related deficiencies. Company plans rapid resolution and Q3 2026 resubmission.